WCM/EADO 2021 | Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, gives an overview of the use of ipilimumab plus nivolumab for the treatment of stage III melanoma in the neoadjuvant setting, highlighting findings from a pooled analysis of six trials. He describes the limitations of targeted therapy and outlines the benefits of nivolumab and ipilimumab combinations in comparison to monotherapy approaches. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Christian Blank, MD, PhD, has participated in an advisory role with BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures; has received research funding from BMS, Novartis and NanoString; is a stockholder in Uniti Cars; and is the Co-Founder of Immagene BV.
